A 7-year-old alliance between Celgene and Acceleron is paying off with more promising PhIII data for luspatercept

Just days after hitting its first set of marks in a critically important Phase III study, Acceleron $XLRN and its partners at Celgene $CELG say that their prospective blockbuster luspatercept has rung all the right bells in a pivotal study for beta thalassemia.